(Q44117691)

30 November 2017

title

Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial (English)

1 reference

30 November 2017

1 reference

1 reference

1 reference

Mutchnick MG

1

1 reference

30 November 2017

Appelman HD

2

1 reference

30 November 2017

Chung HT

3

1 reference

30 November 2017

Aragona E

4

1 reference

30 November 2017

Gupta TP

5

1 reference

30 November 2017

Cummings GD

6

1 reference

30 November 2017

Waggoner JG

7

1 reference

30 November 2017

Hoofnagle JH

8

1 reference

30 November 2017

Shafritz DA

9

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 September 1991

1 reference

30 November 2017

1 reference

30 November 2017

volume

14

1 reference

30 November 2017

issue

3

1 reference

30 November 2017

page(s)

409-415

1 reference

Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

Evolving concepts of the clinical and serologic consequences of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Approaches to the treatment of hepatitis B virus and delta-related liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Pilot study of recombinant human interleukin 2 for chronic type B hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Levamisole therapy for HBsAg-positive chronic liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Purification and Biological Activity of Thymosin, a Hormone of the Thymus Gland

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Production of biologically active N alpha-desacetylthymosin alpha 1 in Escherichia coli through expression of a chemically synthesized gene.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Thymosin modulation of regulatory T cell function

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Immunoregulatory effects of fraction 5 thymus peptides. I. Thymosin alpha 1 enhances while thymosin beta 4 suppresses the human autologous and allogeneic mixed lymphocyte reaction

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by Nα-desacetylthymosin αl

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Thymic hormones--a clinical update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Defective in vitro gamma interferon production and elevated serum immunoreactive thymosin beta 4 levels in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Detection of hepatitis B virus DNA directly in human serum by a simplified molecular hybridization test: comparison to HBeAg/anti-HBe status in HBsAg carriers.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Immunotherapy of patients with chronic virus B hepatitis. I. Maturation of human T-lymphocytes under influence of calf thymic hormone

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Lymphocyte cytotoxicity in human liver disease using rat hepatocyte monolayer cultures

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Increased thymic hormone responsive suppressor T lymphocyte function in chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Theoretical analysis of conformation and active sites of interferons

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Cell-mediated immunity in liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840140302

7 January 2021

Identifiers

DOI

10.1002/HEP.1840140302

1 reference

30 November 2017

1 reference